BridgeBio Pharma (BBIO) Depreciation & Amortization (CF) (2018 - 2026)

BridgeBio Pharma has reported Depreciation & Amortization (CF) for 9 years, with the latest figure at $1.2 million in Q1 2026.

• Quarterly Depreciation & Amortization (CF) fell 7.63% year-over-year to $1.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.3 million (down 7.41% YoY) and the FY2025 annual result came in at $5.4 million, down 10.55% from the prior year.
• Depreciation & Amortization (CF) retreated to $1.2 million in Q1 2026 per BBIO's latest filing, from $1.4 million in the prior quarter.
• Over five years, Depreciation & Amortization (CF) peaked at $1.9 million in Q1 2022 and troughed at $1.2 million in Q1 2026.
• A 5-year average of $1.5 million and a median of $1.6 million in 2022 frame the typical range for Depreciation & Amortization (CF).
• The widest YoY moves for Depreciation & Amortization (CF): up 520.75% in 2022, down 54.62% in 2022.
• Over 5 years, Depreciation & Amortization (CF) stood at $1.7 million in 2022, then dropped by 4.52% to $1.6 million in 2023, then slipped by 13.75% to $1.4 million in 2024, then increased by 4.97% to $1.4 million in 2025, then slipped by 17.35% to $1.2 million in 2026.
• According to Business Quant data, Depreciation & Amortization (CF) over the past three periods registered $1.2 million, $1.4 million, and $1.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.